Addison, Texas – MDB Capital Holdings, LLC (NASDAQ: MDBH), a venture platform recognized for its focus on deep technology companies, announced a new collaboration with Mayo Clinic to develop small molecule anti-aging therapeutics aimed at improving longevity and preventing age-related diseases.
The collaboration announced today will leverage a patent and know-how agreement to advance research targeting senescent cells linked to aging and chronic disease.
Senescent cells stop dividing and accumulate with age and are thought to play a role in promoting chronic inflammation and a variety of fibrotic diseases, but treatment options are limited. Mayo Clinic research has demonstrated the potential of an approved molecule to selectively eliminate these cells, offering great therapeutic potential to reverse fibrosis in a range of diseases.
Christopher Marlette, CEO and co-founder of MDB, expressed enthusiasm about the partnership, highlighting the company’s efforts to address aging and related diseases. Dr. Andrew J. Haack, assistant professor and researcher at Mayo Clinic, echoed this, highlighting the scientific and clinical expertise Mayo Clinic brings to the partnership.
The global market for longevity and anti-aging therapies is projected to approach $45 billion by 2030, reflecting significant interest and investment in the field. Mayo Clinic has disclosed a financial interest in the technology, and the institution plans to reinvest revenues into its non-profit mission of patient care, education and research.
Founded in 1997, MDB Capital specializes in transforming “big ideas” into valuable public companies, leveraging community-driven capital raising for early-stage pre-revenue companies and post-IPO offerings for public organizations that meet its investment criteria.
The company operates a self-clearing broker-dealer and trading platform, and also provides integrated intellectual property strategy consulting and legal services.
This collaboration marks a strategic move by MDB to leverage cutting-edge research to combat age-related diseases, potentially improving outcomes for patients with a range of conditions. The press release on which this article is based states:
In recent news, MDB Capital Holdings has been active in both strategic partnerships and executive appointments. The Dallas-based company announced a significant agreement with the Mayo Foundation for Medical Education and Research and launched a new entity, MDB Minnesota One, which was formed to develop a small molecule aging platform under a license agreement with Mayo.
The agreement includes an upfront license fee of $150,000 as well as development and fundraising milestones. MDB retains a 67% ownership interest in MinnesotaOne and has also entered into a term stock purchase agreement that allows MDB to invest up to $5 million in exchange for common stock over the next five years.
In addition to this, MDB Capital Holdings has expanded its board of directors with the appointment of financial industry veteran Daniel Torpay, whose extensive experience in forensic accounting and integrity services is expected to strengthen the board’s financial oversight and corporate governance expertise.
His appointment as an independent director is in line with MDB Capital’s commitment to corporate governance and shareholder value. These are the latest developments in the continuing evolution of MDB Capital Holdings.
This article was created with the help of AI and reviewed by an editor. For details, see our Terms of Use.
